Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases
Condition: Carcinoma, Non-Small-Cell Lung Interventions: Drug: Radium-223 dichloride (Xofigo, BAY 88-8223); Drug: Pembrolizumab Sponsor: Bayer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study